Cervicogenic Headache, Cognitive Dysfunction

Sponsor
Konya Beyhekim Training and Research Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05572489
Collaborator
(none)
60
1
12
5

Study Details

Study Description

Brief Summary

The goal of this study was to determine the frequency of cognitive dysfunction in patients with cervicogenic headache.

participants will be asked questions to determine their cognitive status at once.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale

Detailed Description

A set of survey-type questions will be asked to the participants. Pain and fatigue levels of the patients were measured by visual pain scale (VAS), mood states by Beck depression scale (BDI) and Pain catastrophizing scale (Pain catastrophizing scale), quality of life by Short Form-36 (SF-36), and cognitive status by Standard Mini. mental test (SMMT) and Montreal cognitive assessment scale (MOCA).

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
60 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Frequency of Cognitive Dysfunction in Individuals With Cervicogenic Headache
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
patients with cervicogenic headache

visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale

Diagnostic Test: visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
evaluation of pain, fatigue, mood, quality of life, cognitive status

healthy controls

visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale

Diagnostic Test: visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
evaluation of pain, fatigue, mood, quality of life, cognitive status

Outcome Measures

Primary Outcome Measures

  1. cognitive status [01.12.2022]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Inclusion Criteria:

Clinical Diagnosis of cervicogenic headache be over 18

Exclusion Criteria:

those under the age of 18 Those with neurological deficits Those with rheumatic diseases such as fibromyalgia, polymyalgia rheumatica, ankylosing spondylitis, rheumatoid arthritis Surgery in the cervical region in the past 6 months Those with widespread pain, significant pain in another anatomical location (eg, gonarthrosis) Those who use drugs or substances (alcohol, drugs, etc.) that may cause cognitive impairment Those with known neurological diseases such as cerebrovascular disease, MS, Parkinson's, dementia Those with major psychiatric illness Those with communication problems Those who have started psychiatric medical treatment in the last three months Those with significant hearing or vision problems Those with a history of uncontrollable systemic disease (cardiovascular, pulmonary, hepatic, renal, hematological, endocrine..)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Konya Beyhekim Research and Training Hospital Konya Selçuklu Turkey 42060

Sponsors and Collaborators

  • Konya Beyhekim Training and Research Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Savaş Karpuz, Medical doctor, Konya Beyhekim Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT05572489
Other Study ID Numbers:
  • 2021-01-02
First Posted:
Oct 7, 2022
Last Update Posted:
Oct 26, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 26, 2022